Published in Front Microbiol on January 17, 2011
HIV infection and HERV expression: a review. Retrovirology (2012) 1.19
No evidence of murine leukemia virus-related viruses in live attenuated human vaccines. PLoS One (2011) 0.82
Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 83.56
Retracted Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science (2009) 10.76
Retracted Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog (2006) 10.08
A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim (1999) 4.93
An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci U S A (2007) 4.77
On the subspecific origin of the laboratory mouse. Nat Genet (2007) 4.68
Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS One (2010) 4.66
Retracted Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. Proc Natl Acad Sci U S A (2010) 4.31
Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol (2008) 4.25
Viral mutation rates. J Virol (2010) 3.87
Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States. Retrovirology (2010) 3.64
Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells. J Virol (2009) 3.16
A human cell-surface receptor for xenotropic and polytropic murine leukemia viruses: possible role in G protein-coupled signal transduction. Proc Natl Acad Sci U S A (1999) 3.13
Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer. J Virol (2008) 2.83
Cloning and characterization of a cell surface receptor for xenotropic and polytropic murine leukemia viruses. Proc Natl Acad Sci U S A (1999) 2.62
XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH. Urology (2010) 2.55
Frequent simian foamy virus infection in persons occupationally exposed to nonhuman primates. J Virol (2004) 2.44
Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J Virol (2008) 2.27
Detection of xenotropic murine leukemia virus-related virus in normal and tumor tissue of patients from the southern United States with prostate cancer is dependent on specific polymerase chain reaction conditions. J Infect Dis (2010) 2.12
Failure to detect Xenotropic murine leukaemia virus-related virus in Chinese patients with chronic fatigue syndrome. Virol J (2010) 2.06
Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions. J Infect Dis (2010) 2.05
A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate (2008) 2.04
US military smallpox vaccination program experience. JAMA (2003) 2.03
Fibrils of prostatic acid phosphatase fragments boost infections with XMRV (xenotropic murine leukemia virus-related virus), a human retrovirus associated with prostate cancer. J Virol (2009) 2.00
The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome. Nat Rev Urol (2010) 1.94
A cautionary tale of virus and disease. BMC Biol (2010) 1.93
Molecular ecology and natural history of simian foamy virus infection in wild-living chimpanzees. PLoS Pathog (2008) 1.92
Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs. J Virol (2010) 1.85
Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors. Proc Natl Acad Sci U S A (2010) 1.71
Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol (2005) 1.63
Failure to detect xenotropic murine leukemia virus-related virus in blood of individuals at high risk of blood-borne viral infections. J Infect Dis (2010) 1.62
Polymorphisms of the cell surface receptor control mouse susceptibilities to xenotropic and polytropic leukemia viruses. J Virol (1999) 1.55
Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer (2010) 1.44
Horizontal transmission of murine retroviruses. J Virol (1987) 1.41
Xenotropic murine leukemia virus-related gammaretrovirus in respiratory tract. Emerg Infect Dis (2010) 1.40
Host range and cellular tropism of the human exogenous gammaretrovirus XMRV. Virology (2010) 1.38
Virology. A new virus for old diseases? Science (2009) 1.38
Identification and characterization of avian retroviruses in chicken embryo-derived yellow fever vaccines: investigation of transmission to vaccine recipients. J Virol (2003) 1.38
Lack of detection of XMRV in seminal plasma from HIV-1 infected men in The Netherlands. PLoS One (2010) 1.34
Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (1993) 1.32
Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in Dutch prostate cancer patients. Prostate (2010) 1.30
Emergence and persistence of hantaviruses. Curr Top Microbiol Immunol (2007) 1.17
Modes of transmission and genetic diversity of foamy viruses in a Macaca tonkeana colony. Retrovirology (2006) 1.14
Expression of infectious murine leukemia viruses by RAW264.7 cells, a potential complication for studies with a widely used mouse macrophage cell line. Retrovirology (2008) 1.12
Zoonotic aspects of arenavirus infections. Vet Microbiol (2009) 1.10
Mouse retroviruses and chronic fatigue syndrome: Does X (or P) mark the spot? Proc Natl Acad Sci U S A (2010) 1.09
Common inbred strains of the laboratory mouse that are susceptible to infection by mouse xenotropic gammaretroviruses and the human-derived retrovirus XMRV. J Virol (2010) 1.09
Evolution of functional and sequence variants of the mammalian XPR1 receptor for mouse xenotropic gammaretroviruses and the human-derived retrovirus XMRV. J Virol (2010) 1.08
Absence of xenotropic murine leukemia virus-related virus in blood cells of men at risk for and infected with HIV. AIDS (2010) 1.06
Discovery of a new endogenous type C retrovirus (FcEV) in cats: evidence for RD-114 being an FcEV(Gag-Pol)/baboon endogenous virus BaEV(Env) recombinant. J Virol (1999) 1.05
No evidence for XMRV association in pediatric idiopathic diseases in France. Retrovirology (2010) 1.02
Unintended spread of a biosafety level 2 recombinant retrovirus. Retrovirology (2009) 1.02
Current status of xenotropic murine leukemia virus-related retrovirus in chronic fatigue syndrome and prostate cancer: reach for a scorecard, not a prescription pad. J Infect Dis (2010) 1.01
Isolation of an infectious endogenous retrovirus in a proportion of live attenuated vaccines for pets. J Virol (2010) 0.98
The yellow fever vaccine: a history. Yale J Biol Med (2010) 0.98
Endogenous retroviruses as potential hazards for vaccines. Biologicals (2010) 0.94
Mobilization of endogenous retroviruses in mice after infection with an exogenous retrovirus. J Virol (2008) 0.91
Human and animal vaccine contaminations. Biologicals (2010) 0.90
No evidence for infection of human embryonic stem cells by feeder cell-derived murine leukemia viruses. Stem Cells (2005) 0.90
Hantavirus infections: epidemiology and pathogenesis. Microbes Infect (1999) 0.89
Chronic fatigue syndrome: xenotropic murine leukemia virus-related virus, murine leukemia virus, both, or neither? Proc Natl Acad Sci U S A (2010) 0.88
Absence of xenotropic murine leukaemia virus-related virus in Danish patients with multiple sclerosis. J Clin Virol (2010) 0.88
Characterization of RD-114 virus isolated from a commercial canine vaccine manufactured using CRFK cells. J Clin Microbiol (2010) 0.87
PCR and serology find no association between xenotropic murine leukemia virus-related virus (XMRV) and autism. Mol Autism (2010) 0.86
Virology. No meeting of minds on XMRV's role in chronic fatigue, cancer. Science (2010) 0.86
Rabies vaccination. Annu Rev Med (1978) 0.84
The GLN family of murine endogenous retroviruses contains an element competent for infectious viral particle formation. J Virol (2008) 0.84
Active immunization in the United States: developments over the past decade. Clin Microbiol Rev (2001) 0.80
Human diploid cell strains (HDCS) viral vaccines. Dev Biol Stand (1998) 0.79
Regulatory affairs and biotechnology in Europe: III. Introduction into good regulatory practice--validation of virus removal and inactivation. Biotherapy (1993) 0.76
Identification of putative endogenous retroviruses actively transcribed in the brain. Virus Genes (2008) 0.76
BIOLOGICALS FOR THE CONTROL AND THERAPY OF VIRUS DISEASES. Bacteriol Rev (1964) 0.76
Identification of a new human coronavirus. Nat Med (2004) 11.24
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2002) 3.59
Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23
HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res (2005) 2.93
Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS (2004) 2.51
Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther (2006) 2.48
The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog (2007) 2.48
Suppression of RNA interference by adenovirus virus-associated RNA. J Virol (2005) 2.29
A novel pancoronavirus RT-PCR assay: frequent detection of human coronavirus NL63 in children hospitalized with respiratory tract infections in Belgium. BMC Infect Dis (2005) 2.28
Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A (2005) 2.21
Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther (2008) 2.14
RNA interference against viruses: strike and counterstrike. Nat Biotechnol (2007) 2.14
Viral evolution as a tool to improve the tetracycline-regulated gene expression system. J Biol Chem (2004) 2.06
In HIV-1 pathogenesis the die is cast during primary infection. AIDS (2007) 2.04
Croup is associated with the novel coronavirus NL63. PLoS Med (2005) 2.03
Detection of new viruses by VIDISCA. Virus discovery based on cDNA-amplified fragment length polymorphism. Methods Mol Biol (2008) 1.95
Retroviral superinfection resistance. Retrovirology (2005) 1.82
A novel long distance base-pairing interaction in human immunodeficiency virus type 1 RNA occludes the Gag start codon. J Biol Chem (2002) 1.81
Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. J Virol (2002) 1.78
The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle. J Virol (2003) 1.71
Inhibition of virus replication by RNA interference. J Biomed Sci (2003) 1.70
Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res (2008) 1.65
Factor correction as a tool to eliminate between-session variation in replicate experiments: application to molecular biology and retrovirology. Retrovirology (2006) 1.64
Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol (2004) 1.64
Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol (2008) 1.61
The novel human coronaviruses NL63 and HKU1. J Virol (2006) 1.59
Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual. J Virol (2003) 1.57
Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol (2004) 1.53
Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol (2007) 1.52
Multiple secondary structure rearrangements during HIV-1 RNA dimerization. Biochemistry (2002) 1.50
Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference. J Virol (2007) 1.50
Microprocessor, Setx, Xrn2, and Rrp6 co-operate to induce premature termination of transcription by RNAPII. Cell (2012) 1.49
The tRNA primer activation signal in the human immunodeficiency virus type 1 genome is important for initiation and processive elongation of reverse transcription. J Virol (2002) 1.40
Mosaic structure of human coronavirus NL63, one thousand years of evolution. J Mol Biol (2006) 1.40
Proteomic studies reveal coordinated changes in T-cell expression patterns upon infection with human immunodeficiency virus type 1. J Virol (2008) 1.40
Genome structure and transcriptional regulation of human coronavirus NL63. Virol J (2004) 1.39
Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology (2013) 1.37
Human coronavirus NL63, a new respiratory virus. FEMS Microbiol Rev (2006) 1.37
Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology (2010) 1.36
The HIV-1 leader RNA conformational switch regulates RNA dimerization but does not regulate mRNA translation. Biochemistry (2005) 1.36
Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner. J Virol (2004) 1.34
Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+ T lymphocytes. J Clin Invest (2005) 1.34
Lack of detection of XMRV in seminal plasma from HIV-1 infected men in The Netherlands. PLoS One (2010) 1.34
Deep sequencing of virus-infected cells reveals HIV-encoded small RNAs. Nucleic Acids Res (2011) 1.32
A miRNA-tRNA mix-up: tRNA origin of proposed miRNA. RNA Biol (2010) 1.30
A riboswitch regulates RNA dimerization and packaging in human immunodeficiency virus type 1 virions. J Virol (2004) 1.30
Human parechovirus type 1, 3, 4, 5, and 6 detection in picornavirus cultures. J Clin Microbiol (2007) 1.28
A systematic analysis of the effect of target RNA structure on RNA interference. Nucleic Acids Res (2007) 1.27
Dimerization and template switching in the 5' untranslated region between various subtypes of human immunodeficiency virus type 1. J Virol (2003) 1.26
Identifying HIV-1 dual infections. Retrovirology (2007) 1.25
Comparison of single regulated lentiviral vectors with rtTA expression driven by an autoregulatory loop or a constitutive promoter. Nucleic Acids Res (2005) 1.23
Differential susceptibility of naïve, central memory and effector memory T cells to dendritic cell-mediated HIV-1 transmission. Retrovirology (2006) 1.23
The TAR hairpin of human immunodeficiency virus type 1 can be deleted when not required for Tat-mediated activation of transcription. J Virol (2007) 1.22
RNA structure modulates splicing efficiency at the human immunodeficiency virus type 1 major splice donor. J Virol (2007) 1.22
Selection of T1249-resistant human immunodeficiency virus type 1 variants. J Virol (2008) 1.21
Sialoadhesin (CD169) expression in CD14+ cells is upregulated early after HIV-1 infection and increases during disease progression. PLoS One (2007) 1.21
The virion-associated incoming HIV-1 RNA genome is not targeted by RNA interference. Retrovirology (2006) 1.20
Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr (2008) 1.20
Regulated HIV-2 RNA dimerization by means of alternative RNA conformations. Nucleic Acids Res (2002) 1.20
Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands. PLoS One (2009) 1.20
Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J Gen Virol (2006) 1.19
Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN--gp120 interaction. J Virol (2005) 1.19
RNAi suppressors encoded by pathogenic human viruses. Int J Biochem Cell Biol (2008) 1.18
Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Mol Ther (2009) 1.18
Effects of random mutations in the human immunodeficiency virus type 1 transcriptional promoter on viral fitness in different host cell environments. J Virol (2006) 1.16
Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One (2009) 1.16
HIV-1 latency in actively dividing human T cell lines. Retrovirology (2008) 1.16
The NS3 protein of rice hoja blanca virus complements the RNAi suppressor function of HIV-1 Tat. EMBO Rep (2009) 1.13
Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis (2012) 1.13
Inhibition of HIV-1 by fusion inhibitors. Curr Pharm Des (2010) 1.13
Probing alternative foldings of the HIV-1 leader RNA by antisense oligonucleotide scanning arrays. Nucleic Acids Res (2004) 1.12
Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J Biol Chem (2009) 1.11
SHAPE-directed discovery of potent shRNA inhibitors of HIV-1. Mol Ther (2012) 1.11
The biased nucleotide composition of the HIV genome: a constant factor in a highly variable virus. Retrovirology (2012) 1.10
Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. J Virol (2008) 1.10
Sexual transmission of hepatitis C virus in human immunodeficiency virus-negative men who have sex with men: a series of case reports. Sex Transm Dis (2011) 1.10
The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. Retrovirology (2008) 1.10
Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J Virol (2011) 1.09
Triple HIV-1 infection. N Engl J Med (2005) 1.09
Antibacterial and antiviral effects of milk proteins and derivatives thereof. Curr Pharm Des (2003) 1.08
RNAi and cellular miRNAs in infections by mammalian viruses. Methods Mol Biol (2011) 1.08
Survey of the temporal changes in HIV-1 replicative fitness in the Amsterdam Cohort. Virology (2007) 1.08
Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site. J Virol (2006) 1.07
Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob Agents Chemother (2006) 1.07
Dicer-independent processing of short hairpin RNAs. Nucleic Acids Res (2013) 1.06
Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure. AIDS Res Hum Retroviruses (2004) 1.06
Design of extended short hairpin RNAs for HIV-1 inhibition. Nucleic Acids Res (2007) 1.06
The HIV RNA setpoint theory revisited. Retrovirology (2007) 1.06
A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs. J RNAi Gene Silencing (2005) 1.06
HIV-1 drug-resistance and drug-dependence. Retrovirology (2007) 1.05
Long-term inhibition of HIV-1 replication with RNA interference against cellular co-factors. Antiviral Res (2010) 1.05
Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs. Retrovirology (2010) 1.05
A conditionally replicating virus as a novel approach toward an HIV vaccine. Methods Enzymol (2004) 1.05
Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function. J Virol (2011) 1.04
An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection. J Virol (2012) 1.04